Management of immune-related cutaneous adverse events with dupilumab

Management of immune-related cutaneous adverse events with dupilumab

Immune checkpoint inhibitors (ICI) target the PD-1/PD-L1 and CTLA-4 pathways and allows the immune system to deliver antitumor effects. However, it is also associated with well-documented immune-related cutaneous adverse events (ircAEs), affecting up to 70–90% of patients on ICI. In this study, we d...

Full description

Bibliographic Details
Main Authors: Paul Chapman, Mario E Lacouture, Lukas kraehenbuehl, Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Elizabeth A Quigley, Alina Markova
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e007324.full

Internet

https://jitc.bmj.com/content/11/6/e007324.full

Similar Items